Balanced two-stage designs for phase II clinical trials

被引:17
|
作者
Ye, Fei [1 ]
Shyr, Yu [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Biostat, Div Canc Biostat, Nashville, TN 37203 USA
关键词
D O I
10.1177/1740774507084102
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Oncology phase II clinical trials are often designed using Simon's two-stage designs (optimal and 'minimax') for independent observations. Simon's designs do not include the use of correlated observations, and do not balance the sample sizes of the two stages. In these designs, the sample sizes of the two stages can be highly unequal. In certain circumstances, an alternative design option that balances the sample sizes is desirable. Purpose To develop a two-stage phase II design that balances the sample sizes of the first and the second stages, while controlling for type I and type II error rates. Methods We simulated designs based on response rates under various null and alternative hypotheses, type I and type II error constraints, and the degree of correlation in the case of correlated data. For correlated data, Sargent's method is adopted to account for the loss of information due to intra-person correlation. Results Design characteristics for different parameter settings were generated using balanced design method, separately for independent and correlated data. Results were evaluated and compared to the optimal and minimax design. Limitations For correlated data, designs were produced only for trials with half of the participants having one observation and the other half having two. Also, the degree of intra-person correlation was fixed at three levels. Conclusion The balanced design provides an additional choice for two-stage phase 11 trials when the investigators would like to monitor the trial near a study's halfway point. Meanwhile, its total sample sizes are comparable with Simon's designs.
引用
收藏
页码:514 / 524
页数:11
相关论文
共 50 条
  • [1] Spatial two-stage designs for phase II clinical trials
    Kim, Seongho
    Wong, Weng Kee
    [J]. COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2022, 169
  • [2] Adaptive two-stage designs in phase II clinical trials
    Banerjee, Anindita
    Tsiatis, Anastasios A.
    [J]. STATISTICS IN MEDICINE, 2006, 25 (19) : 3382 - 3395
  • [3] Bayesian two-stage designs for phase II clinical trials
    Tan, SB
    Machin, D
    [J]. STATISTICS IN MEDICINE, 2002, 21 (14) : 1991 - 2012
  • [4] Curtailed two-stage designs in Phase II clinical trials
    Chi, Yunchan
    Chen, Chia-Min
    [J]. STATISTICS IN MEDICINE, 2008, 27 (29) : 6175 - 6189
  • [5] Bayesian two-stage designs for phase II clinical trials
    Tan, S. B.
    Machin, D.
    [J]. STATISTICS IN MEDICINE, 2006, 25 (19) : 3407 - 3408
  • [6] Admissible two-stage designs for phase II cancer clinical trials
    Jung, SH
    Lee, T
    Kim, K
    George, SL
    [J]. STATISTICS IN MEDICINE, 2004, 23 (04) : 561 - 569
  • [7] Graphical search for two-stage designs for phase II clinical trials
    Jung, SH
    Carey, M
    Kim, KM
    [J]. CONTROLLED CLINICAL TRIALS, 2001, 22 (04): : 367 - 372
  • [8] Admissible two-stage designs for phase II cancer clinical trials
    Jung, SH
    Lee, T
    Kim, KM
    George, SL
    [J]. CONTROLLED CLINICAL TRIALS, 2003, 24 : 61S - 61S
  • [9] Optimal adaptive two-stage designs for early phase II clinical trials
    Shan, Guogen
    Wilding, Gregory E.
    Hutson, Alan D.
    Gerstenberger, Shawn
    [J]. STATISTICS IN MEDICINE, 2016, 35 (08) : 1257 - 1266
  • [10] Minimax and admissible adaptive two-stage designs in phase II clinical trials
    Guogen Shan
    Hua Zhang
    Tao Jiang
    [J]. BMC Medical Research Methodology, 16